Welcome
New Home-Mid Content
WELCOME
The King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions.
We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.
THE FIRST REGISTRY
With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE.
ANTICOAGULATION TRAINING COURSE
The King’s Thrombosis Centre runs this training course twice a year, which was developed to meet the educational needs of healthcare professionals involved in anticoagulation management. Click here to download an application form and agenda.
EXEMPLAR CENTRE NETWORK WEBSITE
After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website is now managed as part of the National VTE prevention Programme at NHS England. Click the image to access the site.
Latest News
-
Anticoagulation news items. Week commencing 29th June 2020
Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy European Journal of Hospital Pharmacy Retrospective study (n=145) reported that INR target…
-
Anticoagulation news items. Week commencing 22nd June 2020
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure – guidance (TA626) National Institute for Health and Care ExcellenceAvatrombopag is recommended as an option…
-
Anticoagulation news items. Week commencing 15th June 2020
Piperacillin/tazobactam-induced coagulopathy in a patient through a vitamin K-dependent mechanism European Journal of Hospital Pharmacy Case report describes 70-year-old female patient whose INR increased following piperacillin/tazobactam (PTZ). Coagulopathy was reversed…
